CD274 and neoplasm: The tumor genomic profiling, ctDNA analysis, programmed death-ligand 1 (PD-L1) expression, hormonal status, tumor mutational burden, and microsatellite instability status were evaluated and scored to inform the multidrug combination selection proposed by the multidisciplinary molecular tumor board.